FRLN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 vas. 2024 @ 22:37):

Stats
Dzisiejszy wolumen	5 349.00
Średni wolumen	28 144.00
Kapitalizacja rynkowa	28.28M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.569
ATR14	$0.0640 (0.99%)

Wolumen Korelacja

Długi: -0.38 (neutral)

Krótki: 0.00 (neutral)

Signal:(61.011) Neutral

Freeline Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
INVZ	0.906
VEEE	0.895
PSTV	0.891
ISUN	0.891
COMM	0.889
MTCH	0.887
DIBS	0.886
BBIG	0.884
ICCC	0.879
NEGG	0.877

10 Najbardziej negatywne korelacje
TYHT	-0.846
RAM	-0.825
SVFC	-0.82
CPTA	-0.816
ALDX	-0.807
SCR	-0.804
VERX	-0.803
EBSB	-0.803
AAON	-0.802
BLCT	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Freeline Therapeutics Korelacja - Waluta/Towar

0.60
( weak )

0.55
( weak )

-0.56
( weak negative )

0.63
( weak )

0.17
( neutral )

-0.28
( neutral )

Freeline Therapeutics Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2022
Przychody:	$0
Zysk brutto:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-3.93

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-6.81

Financial Reports:

No articles found.

Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.